GPR17 and myeloid sarcoma: In this context, future studies will be aimed at assessing whether GPR17 modulation can be exploited to improve OL metabolism during demyelination/remyelination dynamics in animal models of MS and whether GPR17 dysregulation may correlate with specific metabolic alterations in human MS lesions and in the NAWM.